- Home
- ATXS vs IGR Comparison
ATXS vs IGR Comparison
Compare ATXS & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATXS | IGR |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 645.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATXS | IGR |
|---|---|---|
| Price | $13.10 | $4.38 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 747.7K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $706,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.56 | $3.88 |
| 52 Week High | $13.29 | $5.70 |
Technical Indicators
Market Signals| Indicator | ATXS | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 45.72 |
| Support Level | $12.64 | $4.22 |
| Resistance Level | $13.03 | $4.42 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 92.00 | 75.00 |
Price Performance
Historical ComparisonAbout ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.